menu
    • menu

    Company profile for MYR Pharmaceuticals

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    MYR Pharma is focused on the development of Myrcludex B, a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug targets the protein NTCP on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Myrcludex B has shown an excellent safety profile and antiviral efficacy in several clinical trials. The drug has received Orphan Designatio...
    MYR Pharma is focused on the development of Myrcludex B, a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug targets the protein NTCP on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Myrcludex B has shown an excellent safety profile and antiviral efficacy in several clinical trials. The drug has received Orphan Designations for the treatment of HDV infection from EMA and FDA. Myrcludex B has been added to a short list of drugs eligible for the PRIME (PRIority MEdicine) scheme by the European Medicines Agency

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MYR PharmaceuticalsGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Thomasstr. 10-12 61348 Bad Homburg
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://myr-pharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MYR finance chief Christély takes the helm at MetrioPharm
    MYR finance chief Christély takes the helm at MetrioPharm

    20 Aug 2021

    // Kyle LaHucik FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/ex-myr-finance-chief-joins-covid-19-antiviral-chronic-inflammatory-pharma-metriopharm-as

    Kyle LaHucik FIERCEBIOTECH
    20 Aug 2021
    Share Share
    MYR Pharmaceuticals launches HEPCLUDEX® in Germany, France and Austria
    MYR Pharmaceuticals launches HEPCLUDEX® in Germany, France and Austria

    16 Sep 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/myr-pharmaceuticals-launches-hepcludex-in-germany-france-and-austria-301133006.html

    PRNEWSWIRE
    16 Sep 2020
    Share Share
    MYR receives Conditional Marketing Authorization by the European for HEPCLUDEX®
    MYR receives Conditional Marketing Authorization by the European for HEPCLUDEX®

    04 Aug 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/myr-pharmaceuticals-receives-conditional-marketing-authorization-by-the-european-commission-for-hepcludex-301105418.html

    PRNEWSWIRE
    04 Aug 2020
    Share Share
    MYR Pharmaceuticals has incorporated its first European subsidiary in France
    MYR Pharmaceuticals has incorporated its first European subsidiary in France

    10 Jun 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/myr-pharmaceuticals-has-incorporated-its-first-european-subsidiary-in-france-301073644.html

    PRNEWSWIRE
    10 Jun 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search